Table 2.
Univariate of OS and PFS in the study cohort
| Characteristic | OS | PFS | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age | < 60/ 60 | 1.496 (0.867–2.582) | 0.148 | 0.643 (0.362–1.141) | 0.131 |
| Gender | male/ female | 1.478 (0.857–2.547) | 0.160 | 0.738 (0.425–1.283) | 0.282I |
| WBC (×109/L) | < 10/ ≥ 10 | 0.951 (0.429–2.109) | 0.902 | 1.181 (0.598–2.330) | 0.632 |
| CRP (mg/L) | < 8/ ≥ 8 | 0.914 (0.508–1.645) | 0.765 | 1.096 (0.618–1.943) | 0.753 |
| ALT (U/L) | < 40/ ≥ 40 | 0.869 (0.478–1.580) | 0.645 | 1.929 (0.949–3.919) | 0.069 |
| AST (U/L) | < 45/ ≥ 45 | 0.670 (0.376–1.193) | 0.174 | 1.397(0.727–2.688) | 0.316 |
| ALB (g/L) | < 35/ ≥ 35 | 0.987 (0.535–1.819) | 0.966 | 0.747(0.430–1.299) | 0.302 |
| TBIL (mmol/L) | < 20.5/ ≥20.5 | 0.772 (0.419–1.422) | 0.406 | 2.106 (0.957–4.634) | 0.064 |
| ALP (U/L) | < 100/ ≥ 100 | 0.761 (0.382–1.156) | 0.438 | 1.73(0.744–4.023) | 0.203 |
| GGT (U/L) | < 50/ ≥ 50 | 0.571 (0.294–1.109) | 0.098 | 0.906(0.430–1.909) | 0.796 |
| CA19–9 (U/ml) | < 35/ ≥ 35 | 2.362 (1.235–4.159) | 0.009 | 2.095(1.147–3.829) | 0.016 |
| Tumor diffrerntiation | W/W-M/M/M-H/H | 1.005 (0.976–1.035) | 0.74 | 1.030(1.005–1.057) | 0.020 |
| Tumor diameter (cm) | < 2/≥ 2 | 0.991 (0.557–1.765) | 0.976 | 1.486(0.828–2.666) | 0.184 |
| LNR | < 0.17/≥ 0.17 | 1.982 (1.13–3.479) | 0.017 | 1.880(1.098–3.220) | 0.021 |
| LN metastasis | Absent / Present | 1.408 (0.819–2.423) | 0.216 | 2.328 (1.391–3.895) | 0.001 |
| LN total numbers | < 12/≥ 12 | 0.755 (0.430–1.324) | 0.327 | 0.802 (0.478–1.344) | 0.402 |
| Anatomical location | Pancreatic/Duodenal/ Ampullary | 2.287(1.325–3.948) | 0.003 | 2.542 (1.517–4.262) | < 0.001 |
| Chemotherapy | No/Yes | 1.176(0.682–2.027) | 0.559 | 1.713(1.006–2.915) | 0.051 |
HR hazard ratio, CI confidence interval
Other abbreviations as in Table 1